VERU
Veru Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.64
−0.38%Aug 10, 2026, 10:30 UTC
Veru reported fiscal 2026 third quarter financial results and announced that its Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients.
Source:Aug 4, 2026, 12:30 UTC
Veru announced that the U.S. Patent and Trademark Office issued a notice of allowance for a key methods-of-use patent covering enobosarm in combination with semaglutide for quality weight loss, with patent protection until at least October 2044.
Source:Jul 27, 2026, 12:10 UTC
Veru Inc. announced full enrollment in its Phase 2b PLATEAU clinical trial evaluating enobosarm and semaglutide combination for weight loss.
Source:Jul 2, 2026, 00:00 UTC
Veru Inc. entered into a sales agreement with Oppenheimer & Co. Inc. and Canaccord Genuity LLC to issue and sell up to $21,800,000 of its common stock in an at-the-market equity offering.